Center for Drug Evaluation and Research: Difference between revisions

Line 38: Line 38:


=== Office of New Drugs ===
=== Office of New Drugs ===
:: This office is responsible for oversight of clinical trials and other studies during drug development, and for the evaluation of new drug applications
* This office is responsible for oversight of clinical trials and other studies during drug development, and for the evaluation of new drug applications
:: The Office of New Drugs is divided into several departments based on the indication of the drug (the medical need for which it is being proposed)
* The Office of New Drugs is divided into several departments based on the indication of the drug (the medical need for which it is being proposed)


=== Office of Generic Drugs ===
=== Office of Generic Drugs ===
:: This office reviews generic drug applications to ensure generic drugs are equivalent to their branded forms
* This office reviews generic drug applications to ensure generic drugs are equivalent to their branded forms


=== Office of Strategic Programs ===
=== Office of Strategic Programs ===
:: This office is responsible for business programs, represents CDER in the FDA Bioinformatics Board, and communicates with other agencies  
* This office is responsible for business programs, represents CDER in the FDA Bioinformatics Board, and communicates with other agencies  


=== Office of Pharmaceutical Quality ===
=== Office of Pharmaceutical Quality ===
:: This office is responsible for integrating assessment, inspection, surveillance, policy, and research activities to strengthen pharmaceutical quality on a global scale.  
* This office is responsible for integrating assessment, inspection, surveillance, policy, and research activities to strengthen pharmaceutical quality on a global scale.  


=== Office of Surveillance and Epidemiology ===
=== Office of Surveillance and Epidemiology ===
:: This office is responsible for post-marketing surveillance to identify adverse effects that may not have been apparent during clinical trials, using the [[MedWatch]] program
* This office is responsible for post-marketing surveillance to identify adverse effects that may not have been apparent during clinical trials, using the [[MedWatch]] program


=== Office of Translational Sciences ===
=== Office of Translational Sciences ===
:: This office promotes collaboration across offices in CDER by maintaining databases and biostatistical tools for evaluating drugs
* This office promotes collaboration across offices in CDER by maintaining databases and biostatistical tools for evaluating drugs


=== Office of Medical and Regulatory Policy ===
=== Office of Medical and Regulatory Policy ===
:: This office develops and reviews guidelines pertinent to CDER's mission of ensuring the safety of drugs
* This office develops and reviews guidelines pertinent to CDER's mission of ensuring the safety of drugs


=== Office of Compliance ===
=== Office of Compliance ===
:: This office ensures compliance with regulations relating to drug development and marketing
* This office ensures compliance with regulations relating to drug development and marketing


==History==
==History==